Literature DB >> 8554970

Type I and type III collagen metabolites in adult osteosarcoma patients.

T Wiklund1, C Blomqvist, L Risteli, J Risteli, E Karaharju, I Elomaa.   

Abstract

Three biochemical markers of collagen metabolism were measured in 39 osteosarcoma patients. The pretreatment values did not predict outcome, and the markers showed no consistent change upon development of metastases. Both the age of the patients and the multimodality therapy affected the collagen metabolites. These findings emphasise the need for cautious interpretation of tumour-associated markers.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8554970      PMCID： PMC2074279          DOI： 10.1038/bjc.1996.19

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  14 in total

Review 1.  Relationship of cell growth to the regulation of tissue-specific gene expression during osteoblast differentiation.

Authors:  G S Stein; J B Lian; T A Owen
Journal:  FASEB J       Date:  1990-10       Impact factor: 5.191

2.  Rapid equilibrium radioimmunoassay for the amino-terminal propeptide of human type III procollagen.

Authors:  J Risteli; S Niemi; P Trivedi; O Mäentausta; A P Mowat; L Risteli
Journal:  Clin Chem       Date:  1988-04       Impact factor: 8.327

3.  Adjuvant chemotherapy of high-grade osteosarcoma of the extremity. Updated results of the Multi-Institutional Osteosarcoma Study.

Authors:  M P Link; A M Goorin; M Horowitz; W H Meyer; J Belasco; A Baker; A Ayala; J Shuster
Journal:  Clin Orthop Relat Res       Date:  1991-09       Impact factor: 4.176

4.  Prognostic significance of serum alkaline phosphatase measurements in patients with osteosarcoma treated with adjuvant or neoadjuvant chemotherapy.

Authors:  G Bacci; P Picci; S Ferrari; M Orlandi; P Ruggieri; R Casadei; A Ferraro; R Biagini; A Battistini
Journal:  Cancer       Date:  1993-02-15       Impact factor: 6.860

5.  Impact of chemotherapy on collagen metabolism: a study of serum PIIINP (aminoterminal propeptide of type III procollagen) in advanced sarcomas.

Authors:  T A Wiklund; C P Blomqvist; L Risteli; J Risteli; I Elomaa
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

6.  Aminoterminal propeptide of type III procollagen in serum during wound healing in human beings.

Authors:  K Haukipuro; L Risteli; M I Kairaluoma; J Risteli
Journal:  Surgery       Date:  1990-04       Impact factor: 3.982

7.  Monitoring of multiple myeloma and bone marrow fibrosis with aminoterminal propeptide of type III collagen (PIIINP).

Authors:  T Taube; K Franssila; L Risteli; J Risteli; I Elomaa
Journal:  Br J Haematol       Date:  1992-09       Impact factor: 6.998

8.  Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen.

Authors:  J Melkko; S Niemi; L Risteli; J Risteli
Journal:  Clin Chem       Date:  1990-07       Impact factor: 8.327

9.  Serum concentration of the cross-linked carboxyterminal telopeptide of type I collagen (ICTP) is a useful prognostic indicator in multiple myeloma.

Authors:  I Elomaa; P Virkkunen; L Risteli; J Risteli
Journal:  Br J Cancer       Date:  1992-08       Impact factor: 7.640

10.  Type III collagen metabolism in soft tissue sarcomas.

Authors:  T A Wiklund; I Elomaa; C P Blomqvist; L Risteli; J Risteli
Journal:  Br J Cancer       Date:  1992-02       Impact factor: 7.640
View more
  2 in total

1.  Collagen Type III Metabolism Evaluation in Patients with Malignant Head and Neck Cancer Treated with Radiotherapy.

Authors:  Klaudia Mazurek; Krzysztof Siemianowicz; Wirginia Likus; Ewa Pierzchała; Robert Kwiatkowski; Jarosław Markowski
Journal:  Biomed Res Int       Date:  2018-03-26       Impact factor: 3.411

Review 2.  The role of extracelluar matrix in osteosarcoma progression and metastasis.

Authors:  Juncheng Cui; Dylan Dean; Francis J Hornicek; Zhiwei Chen; Zhenfeng Duan
Journal:  J Exp Clin Cancer Res       Date:  2020-09-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.